The estimated Net Worth of Michael B Hoffman is at least $12.7 million dollars as of 3 January 2022. Mr. Hoffman owns over 37,142 units of Annovis Bio stock worth over $12,152,480 and over the last 19 years he sold ANVS stock worth over $579,294. In addition, he makes $0 as Chairman of the Board at Annovis Bio.
Michael has made over 12 trades of the Annovis Bio stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 37,142 units of ANVS stock worth $133,340 on 3 January 2022.
The largest trade he's ever made was buying 1,000,000 units of Annovis Bio stock on 30 July 2013 worth over $15,000,000. On average, Michael trades about 56,792 units every 216 days since 2005. As of 3 January 2022 he still owns at least 1,416,373 units of Annovis Bio stock.
You can see the complete history of Mr. Hoffman stock trades at the bottom of the page.
Michael B. Hoffman serves as Chairman of the Board of the Company. Mr. Hoffman is the Founder and Managing Partner of Stone Capital Partners, a private equity firm focused on power and renewable energy. He was Partner of Riverstone, senior managing director at the Blackstone Group and managing director at Smith Barney, Harris Upham & Co. He serves as Chairman of Annovis Bio, Onconova, Curative and is on the Board of Rockefeller University.
Michael Hoffman is 68, he's been the Chairman of the Board of Annovis Bio since 2015. There are no older and no younger executives at Annovis Bio.
Michael's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 101 LINDENWOOD DR, SUITE 225, MALVERN, PA, 19355.
Over the last 5 years, insiders at Annovis Bio have traded over $0 worth of Annovis Bio stock and bought 24,481 units worth $662,591 . The most active insiders traders include Michael B Hoffman, Maria Luisa Maccecchini et Jeffrey Brian Mc Groarty. On average, Annovis Bio executives and independent directors trade stock every 138 days with the average trade being worth of $158,018. The most recent stock trade was executed by Maria Luisa Maccecchini on 6 February 2023, trading 52,755 units of ANVS stock currently worth $7,386.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio executives and other stock owners filed with the SEC include: